BioGX Receives CE-IVD Mark for Influenza A, B and Respiratory Syncytial Virus Assay on the BD MAX™ System
BIRMINGHAM, Ala., Oct. 6, 2016 /PRNewswire/ -- BioGX announced it has received CE-IVD marking for its Flu A, Flu B, RSV automated test on Becton, Dickinson and Company's (BD) BD MAX™* system for detection of Influenza A, B and Respiratory Syncytial Virus (RSV). The test is intended to simultaneously detect the presence of Flu A, Flu B and RSV RNA present in nasopharyngeal swabs samples collected from individuals at risk of infection.
The Flu A, Flu B, RSV assay for the BD MAX™ automated real-time PCR instrument is offered in a "snap-in-tube" format (Sample-Ready™). BioGX provides all test-specific real-time PCR components lyophilized in a single tube. The Sample-Ready™ tube snaps into the test-specific position on the BD MAX™ RNA/DNA extraction cartridge supplied by BD.
BioGX Sample-Ready™ assays empower clinical laboratories with the time- and cost-savings of moderate complexity systems such as minimum assay manipulation, simple workflow, and quick turnaround times. Sample-Ready™ lyophilized reagent mixes are designed to be compatible with a variety of automated sample extraction and qPCR systems. BioGX reagent technology affords the flexibility to run automated tests as singles or in batches to fit the needs of a laboratory workflow.
"In developing the Sample-Ready™ family of assays, we listened closely to the needs of our customers and crafted these products to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into any laboratory running the BD MAX™ system. Additional diagnostic tests using this technology will be available soon to further extend our market reach," said Shazi Iqbal, Ph.D., CEO of BioGX.
The Flu A, Flu B, RSV assay for BD MAX™ is sold directly by BioGX and it is not available for sale in the United States at this time. To learn more or request information, visit: www.biogx.com
About BioGX:
BioGX is based in Birmingham, Alabama and operates in a cGMP compliant environment certified to International Standard ISO 13485. BioGX develops molecular products and provides partner-specified formulation and manufacturing services for molecular tests on a platform of a partner's choice. The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms. The Sample-Ready™ technology is at the core of all product offerings for Clinical, Food Safety, Pharma and Water Quality testing. BioGX products are available worldwide through direct sales and distributors.
*BD and BD MAX trademarks are property of Becton, Dickinson and Company.
Logo - http://photos.prnewswire.com/prnh/20161005/415789LOGO
SOURCE BioGX
Share this article